Prelude Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for the treatment of cancer and other diseases. The company was founded in 2016 and is based in Wilmington, Delaware, USA.
Prelude Therapeutics' primary mission is to discover and develop innovative therapies that target key drivers of cancer and other diseases. They use a proprietary drug discovery platform that combines computational biology, medicinal chemistry, and structural biology to identify and develop potential drug candidates.
The company's front running drug is PRMT5 inhibitor PRT543, which is currently in clinical development for the treatment of various types of cancer. PRMT5 is an enzyme involved in regulating gene expression, and its dysregulation has been implicated in various cancers. PRT543 is designed to selectively inhibit PRMT5 and has shown promising preclinical results, leading to its advancement into clinical trials.
The company has been actively expanding its research and development efforts and establishing collaborations with academic institutions and biopharmaceutical partners to accelerate the development of potential therapeutics. Prelude's focus on precision medicine and targeted therapies positions them as a promising player in the oncology drug development space. As clinical trials progress, the company aims to bring innovative treatments to patients with unmet medical needs.